Iterum Therapeutics PLC ITRM
We take great care to ensure that the data presented and summarized in this overview for Iterum Therapeutics plc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in ITRM
Top Purchases
Top Sells
About ITRM
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.
Insider Transactions at ITRM
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 22
2023
|
Michael W. Dunne Director |
BUY
Open market or private purchase
|
Direct |
25,000
+18.02%
|
$25,000
$1.4 P/Share
|
|
Dec 18
2023
|
Michael W. Dunne Director |
BUY
Open market or private purchase
|
Direct |
10,000
+10.13%
|
$10,000
$1.84 P/Share
|
|
Dec 01
2023
|
Sailaja Puttagunta Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,933
-22.05%
|
$5,866
$2.12 P/Share
|
|
Dec 01
2023
|
Sailaja Puttagunta Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,333
+38.52%
|
-
|
|
Nov 22
2023
|
Michael W. Dunne Director |
BUY
Open market or private purchase
|
Direct |
20,000
+20.25%
|
$40,000
$2.03 P/Share
|
|
Nov 20
2023
|
Corey N. Fishman Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+15.52%
|
$10,000
$1.59 P/Share
|
|
Oct 01
2023
|
Michael W. Dunne Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,487
+5.6%
|
-
|
|
Oct 01
2023
|
Ronald Hunt Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,479
+27.64%
|
-
|
|
Jul 01
2023
|
Ronald Hunt Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,796
+23.97%
|
-
|
|
Jul 01
2023
|
Michael W. Dunne Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,779
+3.12%
|
-
|
|
Jun 15
2023
|
Mark Chin Director |
BUY
Exercise of conversion of derivative security
|
Direct |
15,853
+46.41%
|
-
|
|
Jun 15
2023
|
Michael W. Dunne Director |
BUY
Exercise of conversion of derivative security
|
Direct |
15,853
+22.86%
|
-
|
|
Jun 15
2023
|
Beth Hecht Director |
BUY
Exercise of conversion of derivative security
|
Direct |
15,853
+45.7%
|
-
|
|
Apr 01
2023
|
Michael W. Dunne Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,299
+3.34%
|
-
|
|
Apr 01
2023
|
Ronald Hunt Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,041
+25.16%
|
-
|
|
Mar 11
2023
|
Corey N. Fishman Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,683
-11.34%
|
$0
$0.96 P/Share
|
|
Mar 11
2023
|
Corey N. Fishman Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
14,333
+22.23%
|
-
|
|
Mar 11
2023
|
Judith M. Matthews Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,883
-26.17%
|
$0
$0.96 P/Share
|
|
Mar 11
2023
|
Judith M. Matthews Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,666
+37.7%
|
-
|
|
Jan 01
2023
|
Ronald Hunt Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,197
+22.9%
|
-
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 61.1K shares |
|---|---|
| Open market or private purchase | 65K shares |
| Grant, award, or other acquisition | 8.33K shares |
| Payment of exercise price or tax liability | 2.93K shares |
|---|